Companies: 10,795·Total market cap: $144.5T
Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc.

ALGSNASDAQHealthcare● Active
$4.96
+$0.05(+1.02%)
Market Cap$30693581
P/E Ratio
52W High$13.689
52W Low$4.8
Overview

Aligos Therapeutics, Inc. (ALGS) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · ALGS · as of Jun 9, 2026

Key Statistics

EPS (TTM)$-8.69algs eps ttm · algs earnings per shareEarnings history
PE Ratio (TTM)algs pe ratio ttm · algs price to earningsPE Ratio deep dive
Revenue (TTM)$4.7Malgs revenue ttm · algs annual revenueFull revenue history
Dividend YieldNo Dividenddoes algs pay dividends · algs dividend yieldDividend history
Shares Outstanding9.9Malgs shares outstanding · algs floatShares outstanding history
Next EarningsAug 5, 2026Est.algs earnings date · algs next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$2.2M▼ 44.59% YoY
202320242025
aligos therapeutics, inc. revenue · algs revenue 2025
FY 2025Net Income-$24.2M▲ +81.56% YoY
202320242025
aligos therapeutics, inc. net income · algs profit 2025
FY 2025EPS$-2.45▲ +88.30% YoY
202320242025
algs eps · aligos therapeutics, inc. earnings per share 2025
TTM:Revenue: $4.7MNet Income: -$90.3MEPS: $-8.69View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy5 analystsis algs a buy · algs analyst rating
Strong Buy
0
Buy
3
Hold
2
Sell
0
Strong Sell
0
12-Month Price Target
$20.00Low
$4.96Current
$20.00Avg Target303.23% upside
$20.00High
algs price target · algs 12 month forecast

Total: 5 · Buy rate: 60.0%

The ALGS analyst consensus is Buy, based on ratings from 5 Wall Street analysts over the past 3 months. The average 12-month price target is $20.00, representing +303.23% upside from the current price of $4.96.

Stock Performance

Full History
1D+1.02%
1W-6.59%
1M-22.98%
3M-29.45%
YTD-46.78%
1Y-31.02%
5Y-99.34%

About Aligos Therapeutics, Inc.

CEOLawrence Blatt
IPO DateOct 16, 2020
Employees70
CountryUS
Websitealigos.com

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidat…

what is aligos therapeutics, inc. · algs stock overview · aligos therapeutics, inc. company profile · who is aligos therapeutics, inc. ceo · algs NASDAQ · aligos therapeutics, inc. headquarters · aligos therapeutics, inc. business segments

About Stock Overview & Key Data

Aligos Therapeutics, Inc. (ALGS) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Oct 16, 2020. As of the latest trading session, ALGS stock price is $4.96, with a market capitalization of $30.7M. The stock has returned -31.02% over the past 12 months and -46.78% year-to-date.

According to 5 Wall Street analysts, the consensus rating for Aligos Therapeutics, Inc. stock is Buy, with an average 12-month price target of $20.00. In fiscal year 2025, Aligos Therapeutics, Inc. reported revenue of $2.2M and net income of -$24.2M. For detailed data — including Aligos Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Aligos Therapeutics, Inc. (ALGS) stock price is $4.96. The stock is traded on NASDAQ under the ticker symbol ALGS. The 52-week range is $4.80 – $13.69.

ALGS stock priceALGS quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 9, 2026Not investment advice